Celcuity Inc. (NASDAQ:CELC) Short Interest Up 13.2% in June

Celcuity Inc. (NASDAQ:CELC) saw a significant increase in short interest in June. As of June 30th, there was short interest totalling 2,150,000 shares, an increase of 13.2% from the June 15th total of 1,900,000 shares. Based on an average daily volume of 273,700 shares, the days-to-cover ratio is currently 7.9 days.

Celcuity Stock Performance

Celcuity stock traded down $0.52 during midday trading on Wednesday, hitting $18.17. 409,056 shares of the company’s stock were exchanged, compared to its average volume of 256,064. The firm’s 50 day simple moving average is $16.10 and its 200 day simple moving average is $16.42. Celcuity has a 12-month low of $8.39 and a 12-month high of $22.19. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.23 and a current ratio of 11.23. The stock has a market cap of $637.77 million, a price-to-earnings ratio of -6.54 and a beta of 0.81.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.07. Equities research analysts predict that Celcuity will post -2.85 EPS for the current year.

Analyst Ratings Changes

CELC has been the subject of a number of research reports. Craig Hallum reissued a “buy” rating and issued a $27.00 price target (up from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Needham & Company LLC reduced their target price on Celcuity from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, May 31st. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Thursday, May 16th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $40.00 price target on shares of Celcuity in a research report on Thursday, May 16th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CELC. SG Americas Securities LLC acquired a new position in shares of Celcuity during the fourth quarter worth about $139,000. BNP Paribas Financial Markets boosted its holdings in Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after purchasing an additional 3,930 shares in the last quarter. Pale Fire Capital SE increased its position in Celcuity by 38.4% during the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares during the period. Trust Point Inc. purchased a new position in shares of Celcuity during the 4th quarter worth approximately $297,000. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Celcuity by 7.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares during the period. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.